Recent attention to the management of atrial fibrillation (AF) and stroke prevention has emphasised the need to support the use of existing pharmacotherapy through available services and resources, in preference to using the new, more expensive, novel oral anticoagulants. In this regard, general practitioners (GPs) are at the core of care.
Background
Atrial fibrillation (AF) is a major contributor to the burden of stroke in Australia, on the background of an ageing population, and the increasing prevalence of heart disease. 1 Recent Australian data highlight that strokes attributed to AF are often more severe in presentation, with a higher mortality rate, than other types of stroke, 2 consistent with international findings. 3 For this reason, the management of AF has become a clinical priority, with attention focused on the use of antithrombotic and antiarrhythmic therapies.
Previous studies have shown that use of these therapies has been suboptimal, [4] [5] [6] [7] particularly in the at-risk elderly population, with clinicians citing a range of barriers to optimal management, including: difficulty in applying guidelines to clinical practice; concerns about the risk versus benefit of therapy in elderly patients; and lack of adequate support to effectively manage patients using complex anticoagulant or antiarrhythmic therapies. 8, 9 In Australia, as far back as 1997, the National Health and Medical Research Council guidelines 10 11 This has set the scene, over the past decade, for the implementation of targeted interventions to assist general practitioners (GPs) in managing patients with AF, including the use of risk assessment tools, practical guidelines, point-of-care testing for warfarin therapeutic monitoring, and patient education resources.
More recently, the advent of new treatment options, i.e., the novel oral anticoagulants (NOACs), has re-focused attention on the management of AF. 12 Given the significant costs of the NOACs and their potential impact on healthsystem expenditure, a government report's 13 recommendations emphasise the need to optimise management of AF through existing pharmacotherapy (e.g., warfarin), existing services, and resources (e.g., point-ofcare testing). In considering the report's recommendations, it is important to first understand the contemporary approach to the management of persons with AF in general practice. Therefore, the aim of this study was to canvas Australian GPs regarding their approach to managing AF, particularly in relation to stroke prevention therapy, and to identify the range of services they used to support their care of patients.
Method
Study design A structured questionnaire was administered to participating GPs over a three-month period in 2012. The questionnaire was purpose-designed to determine GPs' approaches to the management of patients with AF; access and use of services to support patient care; and factors influencing their management of AF. Approval was granted from the relevant institutional Human Research Ethics Committees (Protocol 12453; HREC 2011-348A).
Sample frame
The participating GPs were from four Divisions of General Practice (DGP) or Medical Locals 14 (more recently known as Primary Health Care Networks) in the state of New South Wales (NSW), Australia, who were originally recruited to participate in an intervention trial addressing stroke prevention in AF. 15 The geographical divisions (i.e., City
Metropolitan (CM), Coastal Region (CR), Regional Urban (RU), Regional Rural (RR)) were purposively selected to accommodate a cross-section of GPs caring for patients from diverse backgrounds (i.e., socio-economic, health status, access to health services) within both rural and urban settings in Australia.
Recruitment methods
GPs were invited to participate in the original intervention trial through advertisements for expressions of interest, which were distributed by the relevant DGP. GPs were then recruited into the trial, subject to meeting eligibility criteria, 15 and invited to complete the questionnaire. All participating GPs were informed that the trial was exploring AF management and the use of therapy for stroke prevention. Eligible GPs were those who: were practicing in one general practice surgery and not across multiple sites or surgeries; practiced in the specified divisions of GP; and provided informed written consent to participate in the study.
Sample size calculation
The sample size was estimated based on previous data as well as the requirements of the intervention trial to which the GPs were originally recruited. 15 For this specific descriptive sub-study, the main trial sample provided sufficient participants to meet the stated objectives; i.e., using a point estimate of 25 per cent (i.e., estimated proportion of GPs using specific services to support their management of AF patients) with 95 per cent confidence and 10 per cent degree of precision, a target of 50 GPs recruited over a three-month period was required (in line with the main trial).
Data collection and analysis
The purpose-designed questionnaire was distributed in paper format to the GPs by the study's project officers (in person), who also verified specific inputs (e.g., clarification regarding the nature of services available in the practice).
Computerised analysis of quantitative data was performed using IBM SPSS Statistics 20 (IBM Corp; Armonk: NY). The Chi-square test, Mann-Whitney U test, and Kruskal-Wallis test were used to examine differences in independent proportions (parametric and non-parametric distributions, respectively). ANOVA was used to test for mean differences in continuous variables. A significance level of five per cent (p<0.05) was set for all analyses. Open-ended responses to specific questions were thematically analysed, using manual inductive coding by the project officer and verified by the lead researcher.
Results

Characteristics of the GPs
On average, the 50 participating GPs were 53.74±9.94 years old with 22.88±10.14 years of experience in practice; 35 (70.0 per cent) were male ( Table 1) . GPs in the City Metropolitan region were older in age than those in other regions (p=0.01). There were no significant differences across the four practice regions in terms of the GPs' gender distribution (p=0.63) or years of experience in practice (p=0.21). The characteristics of the GPs were typical of the wider Australian GP setting in terms of age and years of experience, and comparable to that reported in the Better the Evaluation and Care of Health (BEACH) program (a continuous cross-sectional national study). 16 However, there was a higher proportion of male GPs in the present study (versus 57 per cent in the BEACH program).
Characteristics of the practice setting
Overall, the most common type of setting that these GPs practiced in was a "medium-sized medical centre" (i.e., 4-5 GPs; 30.0 per cent of all GPs) ( Table 1) .
General practice areas of specialisation
While all of the GPs were obviously focused on general/family practice, one-fifth (22 per cent) additionally specialised in Women's Health, followed by Aged Care (14 per cent). Only 10 per cent reported specialising in Heart/Vascular Health (under which the management of AF would fall).
GPs practicing in the Coastal Region and Regional Rural areas reported additional specialties of practice, compared with those in the Regional Urban and City Metropolitan areas; only one GP in the City Metropolitan area reported a specialisation (Aged Care). Among the group of "Other" reported specialty areas (n=5 GPs) were: "anaesthetics" (n=1 GP, Rural Region), "mental health" (n=1 GP, Regional Urban), "skin cancer" (one GP each in the Regional Rural and Coastal Region), and "travel and diving diseases" (n=1 GP, Coastal Region).
Diagnostic services provided in general practice
In regard to the diagnostic and monitoring services provided by these GPs, the most commonly reported were: urine testing (e.g., screening tests, test strips), followed by respiratory tests (e.g., peak flow meters) and cardiovascular (e.g., ECG-electrocardiograms, halter monitors) tests. One GP offered "24-hour blood pressure monitoring" (Coastal Region). Approximately three-quarters of GPs provided onsite pathology collection services. Point-of-care testing (e.g., anticoagulation tests) was offered by most (76 per cent) GPs (Table 1 ). In terms of "other" diagnostic services offered by these GPs, one GP offered "laser" (Regional Urban), and one GP offered "dopplers" (Coastal Region).
Patient support services provided in general practice
In regard to patient support services, 90 per cent of GPs provided home visits as well as access to an on-site practice nurse. Most GPs (70 per cent) also provided access to medication management reviews. Other services reported by GPs included an "off-site after-hours clinic" (one GP) and "pharmacy next door" (one GP).
Overall, there were no major differences across the practice regions in terms of practice type, specialisation, diagnostic services, and patients support services (p>0.05).
Management of patients with atrial fibrillation
Overall, most GPs estimated that one-quarter of their patient base (in their current practice setting) was elderly (i.e., ≥65 years of age); 32 per cent of GPs estimated the proportion to be 10-25 per cent, while 34 per cent estimated it as 25-50 per cent. A higher proportion of GPs practicing in the Coastal Region reported that 50-75 per cent of their patient base was elderly ( Table 1 ). The GPs also estimated that, overall, one-quarter of their elderly patient Responsibility for the management of AF Most GPs (n=49, 98 per cent) reported that they maintained primary responsibility for the management of their patient's AF therapy; only one GP from the total sample reported that a cardiologist was primarily responsible for their patients' AF management, while one GP specifically stated that they maintained responsibility for the patients management in "liaison with the cardiologist" ( Table 2 ).
Specialist management of AF
In relation to specialist management of AF, half of the GPs (n=27, 54 per cent) reported that they referred their patients to specialist management of antiarrhythmic therapy only "when needed", while 32 per cent referred to specialist management "for initial assessment only"; only one GP referred to specialist management "for initial and regular follow-up (complete management)" of their antiarrhythmic therapy (Table 2) . For antithrombotic therapy, a higher proportion of GPs reported that they referred patients to specialist management only "when needed" (n=36, 68 per cent); 20 per cent of GPs indicated referring patients "for initial assessment only". Only one GP referred to specialist management "for initial and regular follow-up (complete management)" of their antithrombotic therapy.
On-site services for the management of AF For more than half of the GPs (n=29 GPs, 59.2 per cent) the monitoring and management of their warfarinised patients comprised testing in a local pathology clinic combined with subsequent GP follow-up and review of results. More than 67.3 per cent of GPs (n=33) provided on-site monitoring and review services (at the general practice) for warfarinised patients. GPs also used on-site practice nurses (n=45 GPs, 90 per cent) and home visits (n=45 GPs, 90 per cent) as part of the support offered to anticoagulated patients.
Determinants of the use of antithrombotic therapy
The GPs were asked to nominate their key determinants (up to a maximum of five) in decision-making for the initiation of antithrombotic therapy in an individual patient, ranking the factors in order of importance (i.e., first, second, third, etc., determinants).
As a first determinant, most commonly stated were the "CHADS 2 score", specifically (n=15 GPs, 29.4 per cent), followed by a generic statement about "stroke risk" (n= 9 GPs, 17.6 per cent), then a "confirmed diagnosis of AF" (n=7 GPs, 13.7 per cent) ( Table 3) .
As a second determinant, most commonly stated were "stroke risk" (n=7 GPs, 13 per cent), "cognitive status/mental status of patient" (n=6 GPs, 11.1 per cent), "patient's comorbidities" (n=5 GPs, 9.3 per cent), and "safety of therapy" (n=5 GPs, 9.3 per cent) ( Table 3) .
As a third determinant, most commonly stated were "cognitive status/mental status of patient" (n=11 GPs, 21.2 per cent), followed by "patient's adherence/compliance" (n=9 GPs, 17.3 per cent), and "confirmed diagnosis of AF" (n= 5 GPs, 9.6 per cent) (Table 3) .
Overall, across all the factors stated by the GPs in any ranking, the most frequently stated determinants were "stroke risk" (n=19, 9.4 per cent) and "CHADS 2 score" (n=17, 8.4 per cent), followed by "patient's adherence/compliance" (n=17, 8.4 per cent), "confirmed AF diagnosis" (n=15, 7.4 per cent), and "patient age" (n=15, 7.4 per cent). "Stroke risk" and "CHADS 2 score" were cited as determinants by 38 per cent (19/50) and 34 per cent (17/50) of GPs, respectively. There were no significant differences in the citation and ranking of determinants across the four practice regions.
Qualitative analysis subsequently categorised the cited determinants into three main themes, aligning with the categorisation of decision-making factors, as reported in previous studies: 17  Perceived benefit of therapy  Risks associated with therapy  Medication safety considerations
The perceived benefit of therapy was ranked as a first priority in the decision to initiate antithrombotic therapy, with the patient's "stroke risk" (as assessed by the CHADS 2 score) cited as the main factor. Additionally, GPs cited the need to "confirm the diagnosis of AF" (potentially indicating consideration as to whether the AF is "permanent" or "chronic") and the overall "treatment" strategy (potentially referring to any advice received from specialists) prior to initiating therapy. Furthermore, GPs mentioned "other cardiovascular problems" and "comorbidities" as influences on decision-making, in recognition of the contribution of these to the overall stroke risk and/or additional indications for antithrombotic therapy. Interestingly, "life quality" was also mentioned here, reflecting consideration of any benefits relative to the risks and management issues for the target elderly population.
Surprisingly, factors associated with the perceived risks of therapy did not rank very highly as key determinants of therapy; the risk of bleeding was not explicitly stated by any of the GPs, although "safety" was generically mentioned. In broad terms, GPs highlighted the need to consider "contraindications" to therapy and the patient's "suitability for anticoagulation", although no specific assessment of the risk of bleeding was mentioned.
Most of the determinants cited by GPs fell within the medication safety theme, describing patient and system factors affecting the day-to-day use and management of therapy. Patient-related factors commonly cited were "age", "adherence/compliance", "cognitive/mental state", "falls risk", and "medication/drug interactions". In regard to system-related factors, "monitoring and support" was the key issue cited. Overall, the GPs were more likely to focus on the medication safety issues that underpinned the success of therapy, than an explicit assessment of the risk of bleeding.
Discussion
Overall, the findings from this study are encouraging, and show an evolution in the approach to managing patients with AF, specifically in managing antithrombotic therapy, in the Australian general practice setting. This temporal improvement in the approach to the management of AF patients suggests that GPs are confident and well-resourced in assuming the primary responsibility for management of these patients, whereas historically GPs referred patients for specialist management usually by cardiologists or neurologists. 8, 18 This may reflect their increased ability to apply treatment guidelines, following the implementation of key interventions over the past decade to address previously reported barriers to the prescription of anticoagulant therapy, i.e., the inability to apply evidencebased guidelines to practice, use of risk assessment tools to assist with decision-making (e.g., CHADS 2 criteria), 19 and concerns about the use of anticoagulants in "elderly" patients. 8, 18 Previous studies have reported an age bias in the prescribing of antithrombotic therapy, with anticoagulants (specifically warfarin) reportedly underused in older persons. 5, [20] [21] [22] However, in the present study, GPs seldom cited "old age" per se as a specific determinant in decisionmaking. Instead, GPs focused on a diverse range of factors that impact on the routine day-to-day management of therapy, the so-called medication safety considerations. Although many of these factors are age-related, e.g., cognitive impairment, functional impairment, and the risk of falls, 23 they can be present in all patients and can be independently assessed and potentially addressed through appropriate patient support services. The de-emphasis on "old age" highlights a more sensitive understanding by GPs of the factors that underpin safe and effective management of therapy. Surprisingly, "frailty" was not mentioned by the GPs as a consideration in decision-making, despite the increasing awareness of this geriatric syndrome; 24 previous studies have reported the impact of frailty on the use of antithrombotic therapy. 25, 26 Following from this it was surprising, however, to note the relative lack of specific consideration regarding the risk of bleeding associated with antithrombotic therapy. None of the GPs explicitly stated that the risk of bleeding was a key determinant in decision-making, and none mentioned bleeding risk assessment tools 27, 28 that may assist with this (unlike the reference to the CHADS 2 criteria 19 when assessing the risk of stroke). This contrasts with previous studies, which have shown that GPs have historically focused on the perceived risks of therapy, over and above the benefits of therapy. 8 To an extent this demonstrates an evolution in the approach to decision-making in primary care, with more emphasis placed on identifying and addressing those factors that increase the risk of bleeding so that anticoagulation can be appropriately prescribed to prevent stroke. 29 Indeed, recent practice guidelines emphasise that bleeding risk assessment tools should be used to identify factors that may increase the risk of bleeding so that they can be appropriately managed or "modified". 30 In this regard, it may be argued that bleeding risk is less a determinant in decision-making per se, and more a consideration in the management of therapy. Another explanation may be that the advent of the NOACs has directed attention to the practical aspects of treatment use, rather than the relative risks of bleeding, which are associated with all anticoagulant therapy. 31 In part, the transition of responsibility of care for AF patients to general practice is the result of increased access to services to support both GPs and patients in the management of therapy. In particular, the implementation of on-site services, such as practice nurses 32, 33 and point-ofcare testing (for monitoring coagulation parameters), 34 has allowed GPs to more closely monitor their patients and streamline care. The fact that GPs have access to relevant services is positive, but more importantly, this study has shown no apparent differences in access between practice settings across a range of geographical areas ranging from metropolitan to regional and rural settings, in contrast to concerns raised in previous studies. 35, 36 Furthermore, there are other medication management services available now to support GPs and their patients. For example, medication management review services [such as Home Medicines Review (HMR) provided by accredited pharmacists], 37 provide a platform for the comprehensive review of an individual's pharmacotherapy and the generation of key recommendations to further optimise therapy. 13 The latter service is important, given that it provides an avenue to assess and monitor a patient's adherence to therapy, 38 which is an issue commonly cited by the GPs as determining the initiation of therapy. 39, 40 The medication management review process also provides a framework for the follow-up and support of patients on anticoagulant therapy, particularly those transitioning from hospital back to primary care. An Australian study has previously demonstrated the benefits of a medication review service complemented by point-of-care testing (for coagulation parameters) in improving the quality of anticoagulation (i.e., time in therapeutic range), improving clinical outcomes, and improving patients' adherence (in terms of persistence) with anticoagulant therapy. 41 In drawing conclusions from the findings of this study, it is important to acknowledge several limitations. First, the findings are based on self-report from a self-selected sample of GPs (who were willing to participate in the study) and it is possible that the responses received may not accurately reflect GPs' actual management of patients; however, the sample is broadly representative of Australian general practice, comparable to that reported in the BEACH program. 16 Second, the range of services accessible by GPs may not be actually used in practice for patient care. Third, the findings are based on the management of AF patients, where warfarin has been the mainstay of therapy; with the expanding access to the NOACs, the management approaches to AF patients may be further evolving. All in all, however, this study provides valuable insight into the contemporary management of AF in Australian general practice. In particular, it shows that it has moved away from emphasis on the "error of commission" to a focus on the "error of omission", such that the benefits of therapy are now considered ahead of the risks. More attention needs to be paid, however, to supporting patients' adherence to therapy.
Conclusion
Australian GPs are actively engaged in managing AF, and are well resourced in terms of services and resources. Importantly, there is a greater focus on the benefits of therapy during decision-making, rather than the risks. However, medication safety considerations affecting routine management of therapy remain key concerns, with patients' cognitive or functional impairments, as well as adherence to therapy, serving as major determinants in decision-making. 
